Euro vs US Dollar

Registrieren Sie sich kostenlos, um Echtzeitkurse, interaktive Charts, Live-Optionsfluss und mehr zu erhalten.

Registrieren

MDGL Madrigal Pharmaceuticals Inc

210,88

-5,89 (-2,72%)

10 Okt 2024 - Geschlossen

Verzögert um 15 Minuten

Form 144 - Report of proposed sale of securities

="/Images/box-checked.jpg" alt="Checkbox checked">

144: Remarks and Signature

Remarks

Date of Notice

09/10/2024

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

/s/ William John Sibold

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

Madrigal Pharmaceuticals (NASDAQ:MDGL)
Historical Stock Chart
Von Sep 2024 bis Okt 2024

Click Here for more Madrigal Pharmaceuticals Charts.

Madrigal Pharmaceuticals (NASDAQ:MDGL)
Historical Stock Chart
Von Okt 2023 bis Okt 2024

Click Here for more Madrigal Pharmaceuticals Charts.

News Madrigal Pharmaceuticals Inc

Madrigal Pharmaceuticals to Participate in the H.C. Wainwright & Co. 8th Annual MASH Investor Conference
Mittwoch 2 Oktober 2024 (1 Woche vor) • GlobeNewswire Inc.

Madrigal Pharmaceuticals Appoints Dr. Michael R. Charlton as Senior Vice President, Clinical Development
Dienstag 1 Oktober 2024 (1 Woche vor) • GlobeNewswire Inc.

Madrigal Pharmaceuticals Announces Publication of Positive Health-Related Quality of Life Results from the Phase 3 MAESTRO-NASH Trial of Rezdiffra™ (resmetirom)
Montag 30 September 2024 (1 Woche vor) • GlobeNewswire Inc.

Form 4 - Statement of changes in beneficial ownership of securities
Donnerstag 12 September 2024 (4 Wochen vor) • Edgar (US Regulatory)

Form 144 - Report of proposed sale of securities
Mittwoch 11 September 2024 (4 Wochen vor) • Edgar (US Regulatory)

Madrigal Pharmaceuticals, Inc. to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
Montag 26 August 2024 (1 Monat vor) • GlobeNewswire Inc.

Form 4 - Statement of changes in beneficial ownership of securities
Dienstag 20 August 2024 (2 Monate vor) • Edgar (US Regulatory)

Form 3 - Initial statement of beneficial ownership of securities
Freitag 16 August 2024 (2 Monate vor) • Edgar (US Regulatory)

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Mittwoch 7 August 2024 (2 Monate vor) • Edgar (US Regulatory)

Form 8-K - Current report
Mittwoch 7 August 2024 (2 Monate vor) • Edgar (US Regulatory)

Madrigal Pharmaceuticals Reports Second-Quarter 2024 Financial Results and Provides Corporate Updates
Mittwoch 7 August 2024 (2 Monate vor) • GlobeNewswire Inc.

Madrigal Pharmaceuticals Appoints Shannon Kelley as General Counsel
Freitag 2 August 2024 (2 Monate vor) • GlobeNewswire Inc.

Weitere Madrigal Pharmaceuticals Inc News-Artikel

Deutsche Lufthansa

Euro vs Sterling

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen